Tuesday, November 17, 2026
RSS


← All Stories

Pharmaceutical

ArriVent’s AVBP Plunges 60% After Lung Cancer Trial Misses Primary Endpoint

ArriVent shares plunged 60% after its lung-cancer trial missed the primary endpoint, despite dose-dependent response rates favoring the high…

Oct 6, 2026
Pharmaceutical

BridgeBio’s $BBIO Gains FDA Priority Review for Oral Infigratinib in Children With Achondroplasia

BridgeBio’s NDA for oral infigratinib received FDA acceptance and Priority Review, creating a closely watched regulatory catalyst for $BBIO.

Oct 6, 2026
Pharmaceutical

Vaxcyte Hits 52-Week High as Phase 3 Data Boosts VAX-31 Prospects

Vaxcyte reached a new 52-week high after positive topline Phase 3 OPUS-1 results strengthened the case for its VAX-31 vaccine.

Oct 5, 2026
Pharmaceutical

Alvotech Shares Jump 13.5% After FDA Clears AVT02 Manufacturing Changes

Alvotech’s $ALVO shares jumped 13.5% after FDA approval of AVT02 manufacturing changes, sharpening the focus on supply and commercial scale-…

Oct 5, 2026
Pharmaceutical

Harrow Expands Ophthalmology Franchise With Completed TYRVAYA Acquisition

Harrow completed its TYRVAYA acquisition, adding the first and only FDA-approved nasal spray for dry eye disease to its ocular surface portf…

Oct 5, 2026
Pharmaceutical

GE HealthCare’s $945 Million Sofie Deal Signals Broader Radiopharmaceutical Push

GE HealthCare’s $945 million Sofie Biosciences acquisition could deepen its precision-imaging strategy while putting integration costs under…

Oct 5, 2026
Pharmaceutical

Qiagen Shares Gain as Strategic-Buyer Talks Raise M&A Speculation

Qiagen shares gained after a report said talks with a strategic buyer had advanced, reviving questions about consolidation in diagnostics.

Oct 4, 2026
Pharmaceutical

Pancreatic Cancer Drug Approval Could Lift Oncology Biotech Sentiment

An FDA approval for metastatic pancreatic cancer may improve sentiment across oncology biotech, though investors still lack company-specific…

Oct 4, 2026
Pharmaceutical

AbbVie’s JUVMO Approval Opens New Parkinson’s Growth Opportunity for Investors

AbbVie’s FDA approval of JUVMO may expand its neurology pipeline and offer a potential diversification catalyst beyond immunology.

Oct 4, 2026
Pharmaceutical

Spyre Therapeutics Insiders Sell More Than $3.6 Million in SYRE Stock Despite Bullish Analyst Coverage

Spyre insiders sold more than $3.6 million in SYRE stock as JPMorgan and Baird maintained bullish views, sharpening the debate over volatili…

Oct 3, 2026
Pharmaceutical

MRNA’s Nasdaq-100 Inclusion Draws Retail Attention to SLS and IBRX

Moderna’s Nasdaq-100 inclusion may increase index-related attention, while retail traders compare smaller biotech names SLS and IBRX.

Oct 3, 2026
Pharmaceutical

AbbVie Wins FDA Approval for JUVMO Parkinson’s Therapy: What ABBV Investors Should Watch

AbbVie’s FDA approval of JUVMO adds a Parkinson’s therapy to its neuroscience portfolio, but commercial execution remains the next test.

Oct 3, 2026